000289935 001__ 289935
000289935 005__ 20250817022024.0
000289935 0247_ $$2doi$$a10.1016/j.lungcan.2024.107802
000289935 0247_ $$2pmid$$apmid:38692217
000289935 0247_ $$2ISSN$$a0169-5002
000289935 0247_ $$2ISSN$$a1872-8332
000289935 0247_ $$2altmetric$$aaltmetric:164905916
000289935 037__ $$aDKFZ-2024-00918
000289935 041__ $$aEnglish
000289935 082__ $$a610
000289935 1001_ $$0P:(DE-He78)9b37a369a2adbd89a4a4cd71075756d0$$aKlotz, Laura Valentina$$b0$$eFirst author$$udkfz
000289935 245__ $$aCombination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
000289935 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000289935 3367_ $$2DRIVER$$aarticle
000289935 3367_ $$2DataCite$$aOutput Types/Journal article
000289935 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1717675616_19029
000289935 3367_ $$2BibTeX$$aARTICLE
000289935 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289935 3367_ $$00$$2EndNote$$aJournal Article
000289935 500__ $$a#EA:B220# / 2024 Jun;192:107802
000289935 520__ $$aThe role of cytoreductive surgery for epithelioid pleural mesothelioma within a multimodal treatment approach remains controversial. Carefully selected patients benefit from cytoreductive surgery and adjuvant chemotherapy, but there is no established biomarker to predict tumor recurrence or progression during the course of the disease. The aim of this study was to identify potential biomarkers to predict therapeutic response in terms of progression-free survival.Between 03/2014 and 08/2022, preoperative blood samples were collected from 76 patients with epithelioid pleural mesothelioma who underwent cytoreductive surgery as part of a multimodal treatment approach. Identification of potential biomarkers was performed by determination of mesothelin and calretinin, as well as specific long non-coding RNAs and microRNAs. Receiver operating characteristic analysis, Kaplan-Meier survival analysis, and Cox regression were used to assess the association between biomarker concentrations and patient recurrence status and survival.MALAT1, GAS5, and calretinin showed statistically significant increased biomarker levels in patients with recurrence in contrast to recurrence-free patients after surgical treatment (p < 0.0001, p = 0.0190, and p = 0.0068, respectively). The combination of the three biomarkers resulted in a sensitivity of 68 % and a specificity of 89 %.MALAT1, GAS5, and calretinin could be potential biomarkers for the prediction of tumor recurrence, improving the benefit from multimodal treatment including cytoreductive surgery.
000289935 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000289935 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289935 650_7 $$2Other$$aBiomarker
000289935 650_7 $$2Other$$aCalretinin
000289935 650_7 $$2Other$$aCytoreductive surgery
000289935 650_7 $$2Other$$aDecortication
000289935 650_7 $$2Other$$aGAS5
000289935 650_7 $$2Other$$aMALAT1
000289935 650_7 $$2Other$$aMesothelioma
000289935 650_7 $$2Other$$aThoracic surgery
000289935 650_7 $$2Other$$aTumor recurrence
000289935 7001_ $$aCasjens, Swaantje$$b1
000289935 7001_ $$aJohnen, Georg$$b2
000289935 7001_ $$aTaeger, Dirk$$b3
000289935 7001_ $$aBrik, Alexander$$b4
000289935 7001_ $$aEichhorn, Florian$$b5
000289935 7001_ $$aFörster, Laura$$b6
000289935 7001_ $$aKaiser, Nina$$b7
000289935 7001_ $$aMuley, Thomas$$b8
000289935 7001_ $$aStolp, Christa$$b9
000289935 7001_ $$aSchneider, Marc$$b10
000289935 7001_ $$aGleichenhagen, Jan$$b11
000289935 7001_ $$aBrüning, Thomas$$b12
000289935 7001_ $$aWinter, Hauke$$b13
000289935 7001_ $$aEichhorn, Martin$$b14
000289935 7001_ $$aWeber, Daniel G$$b15
000289935 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2024.107802$$gVol. 192, p. 107802 -$$p107802$$tLung cancer$$v192$$x0169-5002$$y2024
000289935 8564_ $$uhttps://inrepo02.dkfz.de/record/289935/files/1-s2.0-S0169500224003362-main.pdf
000289935 8564_ $$uhttps://inrepo02.dkfz.de/record/289935/files/1-s2.0-S0169500224003362-main.pdf?subformat=pdfa$$xpdfa
000289935 909CO $$ooai:inrepo02.dkfz.de:289935$$pVDB
000289935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b37a369a2adbd89a4a4cd71075756d0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289935 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000289935 9141_ $$y2024
000289935 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000289935 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2022$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000289935 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLUNG CANCER : 2022$$d2023-10-24
000289935 9201_ $$0I:(DE-He78)B220-20160331$$kB220$$lB220 Molekulare Grundlagen thorakaler Tumoren$$x0
000289935 9200_ $$0I:(DE-He78)B220-20160331$$kB220$$lB220 Molekulare Grundlagen thorakaler Tumoren$$x0
000289935 980__ $$ajournal
000289935 980__ $$aVDB
000289935 980__ $$aI:(DE-He78)B220-20160331
000289935 980__ $$aUNRESTRICTED